Advanced age no barrier to continuous myeloma regimen

VIENNA – Elderly patients over age 75 with newly diagnosed multiple myeloma derive the same survival benefits from continuous lenalidomide and low-dose dexamethasone as those under 75, according to a...

Field of Interest: Oncology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness